blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2550367

EP2550367 - GENES AND GENES COMBINATIONS PREDICTIVE OF EARLY RESPONSE OR NON RESPONSE OF SUBJECTS SUFFERING FROM INFLAMMATORY DISEASE TO CYTOKINE TARGETING DRUGS (CYTD) [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.01.2018
Database last updated on 30.10.2024
FormerThe patent has been granted
Status updated on  17.02.2017
FormerGrant of patent is intended
Status updated on  10.02.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
TC LAND Expression
21, rue de la Noue Bras de Fer Bio Ouest Ile de Nantes
44200 Nantes / FR
[2013/05]
Inventor(s)01 / CERVINO, Alessandra
27 rue Nicolas Appert
F-44100 Nantes / FR
02 / POPA-NITA, Oana Ruxandra
11 bd de la Prairie au Duc, App.33E
F-44200 Nantes / FR
03 / BRAUD, Christophe
80 rue de la Gare
F-44980 Sainte-Luce-sur-Loire / FR
 [2013/05]
Representative(s)Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
[2013/05]
Application number, filing date11711830.724.03.2011
[2017/12]
WO2011EP54569
Priority number, dateUS20110457158P19.01.2011         Original published format: US 457158 P
US20100282732P24.03.2010         Original published format: US 282732 P
[2013/05]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011117366
Date:29.09.2011
Language:EN
[2011/39]
Type: A2 Application without search report 
No.:EP2550367
Date:30.01.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 29.09.2011 takes the place of the publication of the European patent application.
[2013/05]
Type: B1 Patent specification 
No.:EP2550367
Date:22.03.2017
Language:EN
[2017/12]
Search report(s)International search report - published on:EP26.01.2012
ClassificationIPC:C12Q1/68
[2013/05]
CPC:
C12Q1/6883 (EP,US); C12Q1/6809 (US); A61P1/04 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P25/00 (EP);
A61P29/00 (EP); A61P37/02 (EP); A61P9/00 (EP);
C12Q1/6876 (US); C12Q2600/106 (EP,US); C12Q2600/158 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/05]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:GENE UND GENKOMBINATIONEN DIE AUFSCHLUSS GEBEN ÜBER RESPONDER UND NON-RESPONDER / PATIENTEN, DIE AN ENTZÜNDLICHEN KRANKHEITEN LEIDEN UND MIT CYTOKIN-ANTAGONISTEN BEHANDELT WERDEN[2016/07]
English:GENES AND GENES COMBINATIONS PREDICTIVE OF EARLY RESPONSE OR NON RESPONSE OF SUBJECTS SUFFERING FROM INFLAMMATORY DISEASE TO CYTOKINE TARGETING DRUGS (CYTD)[2013/05]
French:GÈNES ET COMBINAISONS DE GÈNES PRÉDICTIFS D'UNE RÉPONSE PRÉCOCE OU D'UNE NON-RÉPONSE DE SUJETS SOUFFRANT D'UNE MALADIE INFLAMMATOIRE À DES MÉDICAMENTS CIBLANT LES CYTOKINES (CYTD)[2013/05]
Former [2013/05]GENE UND GENKOMBINATIONEN ZUR VORHERSAGE DER FRÜHREAKTION ODER NICHTREAKTION VON SUBJEKTEN MIT EINER ENTZÜNDUNGSKRANKHEIT AUF CYTOKINADRESSIERENDE WIRKSTOFFE
Entry into regional phase23.10.2012National basic fee paid 
23.10.2012Designation fee(s) paid 
23.10.2012Examination fee paid 
Examination procedure23.10.2012Examination requested  [2013/05]
07.05.2013Amendment by applicant (claims and/or description)
03.02.2014Despatch of a communication from the examining division (Time limit: M06)
25.07.2014Reply to a communication from the examining division
02.09.2015Despatch of a communication from the examining division (Time limit: M04)
29.12.2015Reply to a communication from the examining division
16.03.2016Communication of intention to grant the patent
25.07.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
06.10.2016Communication of intention to grant the patent
06.02.2017Fee for grant paid
06.02.2017Fee for publishing/printing paid
06.02.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17154875.3  / EP3211097
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.02.2014
Opposition(s)02.01.2018No opposition filed within time limit [2018/09]
Fees paidRenewal fee
11.09.2013Renewal fee patent year 03
29.08.2014Renewal fee patent year 04
25.03.2015Renewal fee patent year 05
29.03.2016Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.03.201303   M06   Fee paid on   11.09.2013
31.03.201404   M06   Fee paid on   29.08.2014
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.03.2011
AL22.03.2017
AT22.03.2017
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
MK22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
TR22.03.2017
IE24.03.2017
LU24.03.2017
MT24.03.2017
BE31.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
[2020/33]
Former [2020/15]HU24.03.2011
AT22.03.2017
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
MK22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
TR22.03.2017
IE24.03.2017
LU24.03.2017
MT24.03.2017
BE31.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2019/51]HU24.03.2011
AT22.03.2017
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
MK22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
IE24.03.2017
LU24.03.2017
MT24.03.2017
BE31.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2019/46]HU24.03.2011
AT22.03.2017
CY22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
IE24.03.2017
LU24.03.2017
MT24.03.2017
BE31.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2019/31]HU24.03.2011
AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
IE24.03.2017
LU24.03.2017
MT24.03.2017
BE31.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/43]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
IE24.03.2017
LU24.03.2017
MT24.03.2017
BE31.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/24]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
IE24.03.2017
LU24.03.2017
BE31.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/13]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SI22.03.2017
SK22.03.2017
SM22.03.2017
IE24.03.2017
LU24.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/10]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
SM22.03.2017
LU24.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/09]AT22.03.2017
CZ22.03.2017
DK22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
SM22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2018/06]AT22.03.2017
CZ22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
MC22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
SM22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2017/51]AT22.03.2017
CZ22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
SM22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
PT24.07.2017
Former [2017/50]AT22.03.2017
CZ22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
PL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
Former [2017/49]AT22.03.2017
CZ22.03.2017
EE22.03.2017
ES22.03.2017
FI22.03.2017
HR22.03.2017
IT22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
RO22.03.2017
RS22.03.2017
SE22.03.2017
SK22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
IS22.07.2017
Former [2017/48]CZ22.03.2017
FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
RS22.03.2017
SE22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
Former [2017/41]FI22.03.2017
HR22.03.2017
LT22.03.2017
LV22.03.2017
NL22.03.2017
RS22.03.2017
SE22.03.2017
BG22.06.2017
NO22.06.2017
GR23.06.2017
Cited inInternational search[Y]WO2007038501  (THE FEINSTEIN INST MEDICAL RES [US], et al) [Y] 1-28 * paragraph [0023] - paragraph [0072]; figures 3-5; claims 1-26 *;
 [Y]EP1857559  (INST NAT SANTE RECH MED [FR]) [Y] 1-28 * paragraphs [0007 ] - [ 0061]; figure 1; claims 1-19 *;
 [X]WO2008087647  (YEDA RES & DEV [IL], et al) [X] 1-10,12,14-20,23,25-28 * claims 1-13 *;
 [X]WO2008132176  (UNIV LOUVAIN [BE], et al) [X] 1-10,12,14-20,23,25-28 * the whole document *;
 [Y]WO2008150491  (ABBOTT LAB [US], et al) [Y] 1-28 * page 2 - page 40; claims 1-68 *;
 [XP]WO2010034864  (FUNDACIO INST DE RECERCA DE L [ES], et al) [XP] 1-10,12,14-20,23,25-28 * the whole document *;
 [Y]  - LEQUERRE T ET AL, "GENE EXPRESSION PROFILING IN PBMCS AS A TOOL FOR PREDICTION OF INFLIXIMAB RESPONSIVENESS IN RHEUMATOID ARTHRITIS", ARTHRITIS & RHEUMATISM, JOHN WILEY & SONS, INC, US, (20040101), ISSN 0004-3591, XP008067698 [Y] 1-28 * the whole document *
 [Y]  - LINDBERG JOHAN ET AL, "Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, (20061129), vol. 8, no. 6, doi:DOI:10.1186/AR2090, ISSN 1478-6354, page R179, XP021026935 [Y] 1-28 * the whole document *

DOI:   http://dx.doi.org/10.1186/ar2090
 [Y]  - LEQUERRÉ THIERRY ET AL, "Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, (20060703), vol. 8, no. 4, doi:DOI:10.1186/AR1924, ISSN 1478-6354, page R105, XP021020585 [Y] 1-28 * the whole document *

DOI:   http://dx.doi.org/10.1186/ar1924
 [Y]  - HAEUPL T ET AL, "GENE EXPRESSION PROFILING OF RHEUMATOID ARTHRITIS SYNOVIAL CELLS TREATED WITH ANTIRHEUMATIC DRUGS", JOURNAL OF BIOMOLECULAR SCREENING, LARCHMONT, NY, US, (20070101), vol. 12, no. 3, doi:DOI:10.1177/1087057107299261, ISSN 1087-0571, pages 328 - 340, XP009083067 [Y] 1-28 * the whole document *

DOI:   http://dx.doi.org/10.1177/1087057107299261
 [X]  - KRUITHOF ELLI ET AL, "Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis", ARTHRITIS & RHEUMATISM, (200606), vol. 54, no. 6, ISSN 0004-3591, pages 1795 - 1804, XP002662897 [X] 1-10,12,14-20,23,25-28 * the whole document *

DOI:   http://dx.doi.org/10.1002/ART.21914
ExaminationWO2006063856
 WO2008063414
by applicant   - LEE DM, WEINBLATT ME., "Rheumatoid arthritis", LANCET, (20010915), vol. 358, no. 9285, doi:doi:10.1016/S0140-6736(01)06075-5, pages 903 - 11, XP004806356

DOI:   http://dx.doi.org/10.1016/S0140-6736(01)06075-5
    - CHOY EH, PANAYI GS., "Cytokine pathways and joint inflammation in rheumatoid arthritis", N ENGL J MED., (20010322), vol. 344, no. 12, pages 907 - 16
    - KOOLOOS WM, DE JONG DJ, HUIZINGA TW, GUCHELAAR HJ., "Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease", DRUG DISCOVERY TODAY, (2007), vol. 12, no. 3-4, doi:doi:10.1016/j.drudis.2006.11.013, pages 125 - 31, XP005867978

DOI:   http://dx.doi.org/10.1016/j.drudis.2006.11.013
    - ISAACS JD., "Antibody engineering to develop new antirheumatic therapies", ARTHRITIS RES THER., (2009), vol. 11, no. 3, doi:doi:10.1186/ar2594, page 225, XP055025781

DOI:   http://dx.doi.org/10.1186/ar2594
    - HETLAND ML, CHRISTENSEN IJ, TARP U, DREYER L, HANSEN A, HANSEN IT ET AL., "Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry", ARTHRITIS RHEUM., (201001), vol. 62, no. 1, pages 22 - 32
    - LEQUERRE T, GAUTHIER-JAUNEAU AC, BANSARD C, DERAMBURE C, HIRON M, VITTECOQ O ET AL., "Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis", ARTHRITIS RES THER., (2006), vol. 8, no. 4, doi:doi:10.1186/ar1924, page R105, XP021020585

DOI:   http://dx.doi.org/10.1186/ar1924
    - SEKIGUCHI N, KAWAUCHI S, FURUYA T, INABA N, MATSUDA K, ANDO S ET AL., "Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody", INFLIXIMAB. RHEUMATOLOGY, (200806), vol. 47, no. 6, doi:doi:10.1093/rheumatology/ken083, pages 780 - 8, XP002562468

DOI:   http://dx.doi.org/10.1093/rheumatology/ken083
    - JULIA A, ERRA A, PALACIO C, TOMAS C, SANS X, BARCELO P ET AL., "An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis", PLOS ONE, (2009), vol. 4, no. 10, doi:doi:10.1371/journal.pone.0007556, page E7556, XP055015104

DOI:   http://dx.doi.org/10.1371/journal.pone.0007556
    - BIENKOWSKA JR, DALGIN GS, BATLIWALLA F, ALLAIRE N, ROUBENOFF R, GREGERSEN PK ET AL., "Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response", GENOMICS, (200912), vol. 94, no. 6, doi:doi:10.1016/j.ygeno.2009.08.008, pages 423 - 32, XP026754299

DOI:   http://dx.doi.org/10.1016/j.ygeno.2009.08.008
    - RAMASAMY A, MONDRY A, HOLMES CC, ALTMAN DG., "Key issues in conducting a meta-analysis of gene expression microarray datasets", PLOS MED., (20080930), vol. 5, no. 9, page E184
    - ARNETT FC, EDWORTHY SM, BLOCH DA, MCSHANE DJ, FRIES JF, COOPER NS ET AL., "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", ARTHRITIS RHEUM., (198803), vol. 31, no. 3, pages 315 - 24
    - PARMIGIANI G, GARRETT-MAYER ES, ANBAZHAGAN R, GABRIELSON E., "A cross-study comparison of gene expression studies for the molecular classification of lung cancer", CLIN CANCER RES., (20040501), vol. 10, no. 9, doi:doi:10.1158/1078-0432.CCR-03-0490, pages 2922 - 7, XP002365384

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-03-0490
    - BARTON A, THOMSON W, KE X, EYRE S, HINKS A, BOWES J ET AL., "Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13", NAT GENET., (200810), vol. 40, no. 10, pages 1156 - 9
    - GORONZY JJ, WEYAND CM., "Developments in the scientific understanding of rheumatoid arthritis", ARTHRITIS RES THER., (2009), vol. 11, no. 5, doi:doi:10.1186/ar2758, page 249, XP055026759

DOI:   http://dx.doi.org/10.1186/ar2758
    - LORENZ E, MUHLEBACH MS, TESSIER PA, ALEXIS NE, DUNCAN HITE R, SEEDS MC ET AL., "Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases", RESPIR MED., (200804), vol. 102, no. 4, pages 567 - 73, XP022506415
    - CHENG P, CORZO CA, LUETTEKE N, YU B, NAGARAJ S, BUI MM ET AL., "Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein", J EXP MED., (20080929), vol. 205, no. 10, pages 2235 - 49
    - LIM SY, RAFTERY M, GOYETTE J, HSU K, GECZY CL., "Oxidative modifications of S100 proteins: functional regulation by redox", J LEUKOC BIOL., (2009), vol. 86, no. 3, pages 577 - 87
    - CHEN YS, YAN W, GECZY CL, BROWN MA, THOMAS R., "Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis", ARTHRITIS RES THER., (2009), vol. 11, no. 2, doi:doi:10.1186/ar2645, page R39, XP021053404

DOI:   http://dx.doi.org/10.1186/ar2645
    - GROH V, BRUHL A, EI-GABALAWY H, NELSON JL, SPIES T., "Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis", PROC NATL ACAD SCI USA., (20030805), vol. 100, no. 16, doi:doi:10.1073/PNAS.1632807100, pages 9452 - 7, XP002610085

DOI:   http://dx.doi.org/10.1073/PNAS.1632807100
    - PAUL R, OBERMAIER B, VAN ZIFFLE J, ANGELE B, PFISTER HW, LOWELL CA ET AL., "Myeloid Src kinases regulate phagocytosis and oxidative burst in pneumococcal meningitis by activating NADPH oxidase", J LEUKOC BIOL., (200810), vol. 84, no. 4, pages 1141 - 50
    - FUMAGALLI L, ZHANG H, BARUZZI A, LOWELL CA, BERTON G., "The Src family kinases Hck and Fgr regulate neutrophil responses to N-formyl-methionyl-leucyl-phenylalanine", J IMMUNOL., (20070315), vol. 178, no. 6, pages 3874 - 85
    - MOCSAI A, LIGETI E, LOWELL CA, BERTON G., "Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck", J IMMUNOL., (19990115), vol. 162, no. 2, pages 1120 - 6
    - BOSCO MC, CURIEL RE, ZEA AH, MALABARBA MG, ORTALDO JR, ESPINOZA-DELGADO ., "IL-2 signaling in human monocytes involves the phosphorylation and activation of p59hck.", J IMMUNOL., (20000501), vol. 164, no. 9, pages 4575 - 85
    - DENG A, CHEN S, LI Q, LYU SC, CLAYBERGER C, KRENSKY AM., "Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator", J IMMUNOL., (20050501), vol. 174, no. 9, doi:doi:10.4049/jimmunol.174.9.5243, pages 5243 - 8, XP002713791

DOI:   http://dx.doi.org/10.4049/jimmunol.174.9.5243
    - KRENSKY AM, CLAYBERGER C., "Biology and clinical relevance of granulysin.", TISSUE ANTIGENS, (200903), vol. 73, no. 3, doi:doi:10.1111/j.1399-0039.2008.01218.x, pages 193 - 8, XP009136038

DOI:   http://dx.doi.org/10.1111/j.1399-0039.2008.01218.x
    - MARTINON F, TSCHOPP J., "Inflammatory caspases and inflammasomes: master switches of inflammation", CELL DEATH DIFFER., (200701), vol. 14, no. 1, pages 10 - 22
    - KUROKAWA M, KORNBLUTH S., "Caspases and kinases in a death grip", CELL, (20090904), vol. 138, no. 5, pages 838 - 54
    - MOREL J, AUDO R, HAHNE M, COMBE B., "Tumor necrosis factor-related apoptosis- inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.", J BIOL CHEM., (20050422), vol. 280, no. 16, pages 15709 - 18
    - KORB A, TOHIDAST-AKRAD M, CETIN E, AXMANN R, SMOLEN J, SCHETT G., "Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis", ARTHRITIS RHEUM., (200609), vol. 54, no. 9, pages 2745 - 31
    - FRANSEN J, VAN RIEL PLCM, "The Disease Activity Score and the EULAR response criteria", CLIN EXP RHEUMATOL., (2005), vol. 23, no. 5, pages 93 - 9
    - LORENZ HM ET AL., ARTHRITIS RES., (2002), vol. 4, no. 3, pages 17 - 24
    - ATZENI F ET AL., AUTOIMMUN REV., (200709), vol. 6, no. 8, pages 529 - 36
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.